The TAT Honorary Award was established to acknowledge distinguished cancer drug development experts who have devoted a major part of their careers to the discovery and development of better anticancer medicines.
The TAT Honorary Award was established in the early 1990s to acknowledge distinguished cancer drug development experts who have devoted a major part of their careers to the discovery and development of better anticancer medicines.
TAT 2020 Honorary Award recipient
Lillian L. Siu, Professor at the University of Toronto and Medical Oncologist at the Princess Margaret Cancer Centre, Toronto, will receive the TAT 2020 Honorary Award in recognition of her pivotal contributions in the development of new anticancer drugs, particularly with respect to phase I trials in head and neck malignancies. The award will be presented during the ESMO Targeted Anticancer Therapies Congress, to be held in Paris, France, 2-4 March.
I am immensely honoured to receive this award, which is particularly special to me as it recognises my work in the field of early drug development as impactful for the community. The TAT Congress is a unique nexus that catalyses advancements in oncological therapeutics by translating emerging knowledge in cancer biology and host immune system into clinical applications, and by incorporating technological advances to decode and characterise tumours and their microenvironment. With a growing armamentarium of anticancer agents, it is an exciting time to be an early drug developer.
Past TAT Honorary Award recipients
- Geoffrey Shapiro (2019)
- Jean-Charles Soria (2018)
- Jedd D. Wolchok (2017)
- Anthony Tolcher (2016)
- Hilary Calvert (2015)
- Patricia LoRusso (2014)
- Jean-Pierre Armand (2013)
- Elizabeth Eisenhauer (2012)
- Giuseppe Giaccone (2011)
- Axel Ullrich (2010)
- Napoleone Ferrara (2009)
- Julian Adams (2008)
Nomination and selection process
The recipient is nominated by the International Congress on Targeted Anticancer Therapies (TAT) Scientific Committee.
The award consists of the opportunity to give a scientific keynote lecture, a prize and free registration, free accommodation and reimbursement of travel expenses to the TAT Congress.
The TAT Scientific Committee is requested to nominate candidates who must:
- be a distinguished cancer drug development expert, who has devoted a major part of their career to the discovery and development of better anticancer medicines
- demonstrate an affiliation to a major academic or cancer research or treatment institution
- have published articles on drug development in highly cited peer-reviewed journals
- be an ESMO member
- not be a current member of the ESMO Executive Board or the ESMO Nomination Committee, nor have served on these committees within the last two years
- not be a TAT Scientific Committee member
- not be a past TAT Honorary Award recipient
All nominations are evaluated, and a final awardee is selected by the ESMO President, in collaboration with the TAT Congress Steering Committee Chair and the ESMO Nomination Committee Chair.